Drug Research

Researchers in Singapore have identified a brand-new therapeutic target called ADAM10 that may be used to treat people who have diabetic retinopathy (DR), a disorder that is brought on by untreated diabetes and results in blindness. A typical symptom of...

Eli Lilly and Company and ProQR Therapeutics N.V. announced the expansion of their licensing and collaboration agreement focused on the discovery, development and commercialization of new genetic medicines. The collaboration, originally announced in September 2021, applied ProQR’s proprietary Axiomer® RNA editing...

Berkshire Sterile Manufacturing (BSM), a Massachusetts-based fill finish CDMO, recently purchased and validated three new analytical instruments to expand its testing and development capabilities. While the company’s primary service offering is sterile filtration and filling of parenterals, BSM also provides...

Global contract development and manufacturing organization Micro-Sphere has launched a new, 200 square-foot research and development (R&D) lab to strengthen its services in formulation development and inhalation. Located within its facility in Monteggio, Switzerland, the new R&D department will specialize...

Asymchem Laboratories (Tianjin) Co. Ltd., a CDMO serving the global pharmaceutical and biotech industry, has opened a new site in Woburn, Massachusetts. Asymchem Boston, a wholly owned subsidiary of Asymchem Group, marks an important step toward expanding Asymchem's global footprint....

An Italian study that was recently published in Neurology, the official journal of the American Academy of Neurology, suggests that hematopoietic stem cell transplants may help persons having active secondary progressive multiple sclerosis (MS) delay disability. The ten-year retrospective study...

Multiple provisions crucial to FDA operations and authority, in addition to clinical research sponsors and pharmaceutical manufacturers, are included in the year-end, must-pass government spending bill. Along with dozens of measures involving drug development and regulation, the $1.7 billion...